Our Paper of the Month for May 2023 is a significant step forward in the field of Alzheimer’s disease treatment and could profoundly impact future research and patient care. The promising phase 1b trial using an antisense oligonucleotide (MAPTRx) shows potential in reducing tau protein levels in mild Alzheimer’s Disease patients.
We asked Prof. Kristian Steen Frederiksen, Co-Chair of the EAN Scientific Panel on Dementia and Cognitive Disorders, three key questions about this groundbreaking study:
- What are the objectives and main results of the study?
- Do you think these results are relevant to the community of neurologists?
- What is your opinion on the perspectives opened by these new data?
Watch the video below for Prof. Frederiksen’s answers and read our full report on the paper here.
